Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J. Morris, José Maurício Mota, Kristine Peregrino Lacuna, Patrick Hilden, Martin Gleave, Michael A. Carducci, Fred Saad, Erica Simone Dayan, Julie Filipenko, Glenn Heller, Neal D. Shore, Andrew J. Armstrong, Howard I. Scher
Topics & Concepts
MedicineDocetaxelClinical endpointProstate cancerHazard ratioAndrogen deprivation therapyPopulationProstatectomyInternal medicineUrologyTestosterone (patch)Prostate-specific antigenBiochemical recurrenceRandomized controlled trialConfidence intervalOncologyCancerEnvironmental healthProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentUrinary Bladder and Prostate Research